Moreover, the increase in plasma [Kyn] in patients with cancer can also result from an additional increase in the flux of plasma free Trp down the KP and also a potential inhibition (down-regulation) of KMO, as occurs in many cancer types [73]: all being determinants of the [Kyn]/[Trp] ratio [5]. Here, KMO is linked to cancer.